Form 4: Astrana Health COO/CFO Sells Shares for Tax Obligations

Astrana Health's COO and CFO, Chandan Basho, disposed of 1,694 shares of common stock to cover tax liabilities related to vested restricted stock units.

Summary

• Chandan Basho, the Chief Operating Officer and Chief Financial Officer of Astrana Health, Inc. (ASTH), reported a transaction involving the company's common stock.
• On September 5, 2025, Mr. Basho disposed of 1,694 shares of common stock at a price of $29.7 per share.
• This disposition was a 'tax withholding' transaction (Code F), meaning shares were surrendered to offset tax obligations associated with restricted stock units that vested on the same date.
• Following this transaction, Mr. Basho beneficially owns 176,946 shares of common stock.
• The remaining beneficial ownership includes 7,214 shares of unvested restricted stock vesting on April 14, 2026, and 30,404 shares vesting in two equal annual installments on May 16, 2026, and May 16, 2027.
• Additionally, the beneficial ownership includes 23,404 restricted stock units vesting in six equal semi-annual installments starting October 2, 2025, and 23,364 restricted stock units vesting in seven equal semi-annual installments starting March 5, 2026.

Sentiment

Score: 5

Explanation: The filing reports a routine, tax-related insider transaction. It is neither significantly positive nor negative for the company's operational or financial outlook, representing a standard compensation event.

Positives

• The underlying event for the transaction was the vesting of restricted stock units, indicating the executive is realizing earned compensation.
• The transaction is a routine tax-related disposition, which is a standard practice for executives receiving equity compensation.

Negatives

• The disposition of 1,694 shares, while for tax purposes, represents a slight reduction in the executive's direct shareholding.

Future Outlook

The executive's future equity holdings are structured with several vesting schedules extending through May 2027, contingent on continuous employment. This indicates a long-term incentive structure for the COO and CFO.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries for executives receiving equity-based compensation. It does not provide specific industry-wide insights.

Comparison to Industry Standards

• Not applicable as this is a routine insider transaction report for tax purposes, which is a standard practice for executives across publicly traded companies receiving equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related disposition of a relatively small number of shares by an executive.
• Employees: No direct impact mentioned, but the vesting of equity compensation is a standard practice for executive incentives.

Next Steps

• Continued vesting of 23,404 restricted stock units in six equal semi-annual installments beginning October 2, 2025.
• Continued vesting of 23,364 restricted stock units in seven equal semi-annual installments beginning March 5, 2026.
• Vesting of 7,214 shares of unvested restricted stock on April 14, 2026.
• Vesting of 30,404 shares of unvested restricted stock in two equal annual installments on May 16, 2026, and May 16, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine, tax-related disposition of shares by a key executive following the vesting of restricted stock units. Such transactions are standard practice and do not typically indicate a change in the company's fundamentals or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Astrana Health, ASTH, Chandan Basho, Form 4, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Equity Compensation